Table 4.
Antihypertensive drugs at 6- and 12-month of follow-up.
| 6-month of follow-up | 12-month of follow-up | |||||
|---|---|---|---|---|---|---|
| UC | TBC | p-value | UC | TBC | p-value | |
| n = 42 | n = 39 | n = 41 | n = 35 | |||
| Number of antihypertensive drugs, mean (SD) | 2.1 (0.9) | 2.1 (1.0) | 0.93 | 2.1 (0.9) | 2.3 (0.9) | 0.43 |
| Number of antihypertensive drugs, n (%) | 0.33 | 0.62 | ||||
| 0 | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | ||
| 1 | 12 (29%) | 13 (33%) | 10 (24%) | 7 (20%) | ||
| 2 | 19 (45%) | 11 (28%) | 20 (49%) | 15 (43%) | ||
| ≥ 3 | 11 (26%) | 14 (36%) | 11 (27%) | 13 (37%) | ||
| Class of antihypertensive drugs used, n (%) | 0.68 | 0.57 | ||||
| Diuretics | 21 (52%) | 16 (41%) | 22 (54%) | 19 (54%) | ||
| ACE inhibitors | 12 (29%) | 13 (33%) | 11 (27%) | 14 (40%) | ||
| Ang II receptor blockers | 27 (64%) | 22 (56%) | 27 (66%) | 22 (63%) | ||
| Calcium antagonists | 13 (31%) | 17 (44%) | 14 (34%) | 12 (34%) | ||
| Beta-blockers | 9 (21%) | 12 (31%) | 8 (20%) | 12 (34%) | ||
| Other | 1 (3%) | 0 (0%) | 2 (5%) | 0 (0%) | ||
| Antihypertensive-drug modifications | ||||||
| Drug changes (change to another class of drug), n (%) | 2 (5%) | 6 (15%) | 0.11 | 4 (10%) | 9 (26%) | 0.07 |
| Drug intensifications (increase of dosage or number of drugs), n (%) | 14 (33%) | 19 (49%) | 0.16 | 17 (41%) | 21 (60%) | 0.11 |
| Drug reductions (decrease of dosage or number of drugs), n (%) | 4 (10%) | 7 (18%) | 0.27 | 6 (15%) | 4 (11%) | 0.68 |
| Any drug modification, n (%) | 17 (40%) | 21 (54%) | 0.23 | 24 (59%) | 24 (69%) | 0.37 |
| Mean number of drug modifications/patient (min–max) | 0.6 (0–3) | 1.1 (0–4) | 0.04 | 0.9 (0–3) | 1.3 (0–4) | 0.06 |
UC, usual care; TBC, team-based care; SD, standard deviation; ACE, angiotensin converting enzyme; Ang, angiotensin.